Methods:
We used Washington State surveillance data to identify women 14 years or older with urogenital CT (1992-2015) treated with azithromycin or doxycycline. We defined persistent/recurrent CT as a repeat positive CT test result 14 to 180 days after treatment of the initial infection. We used log binomial regression to estimate the adjusted relative risk (aRR) of persistent/recurrent infection associated with treatment with azithromycin versus doxycycline.
Results: From 1992 to 2015, there were 268,596 reported cases of urogenital CT, including 168,301 (63%) who received azithromycin and 66,432 (25%) who received doxycycline. The risk of persistent/recurrent urogenital CTwas 6.7% and 4.7% in azithromycin-and doxycycline-treated cases, respectively (P < 0.001). Adjusting for age, race/ethnicity, year, pregnancy status, jurisdiction reporting, reason for examination, and gonorrhea coinfection, azithromycin-treated women were significantly more likely to have persistent/recurrent urogenital CT than doxycycline-treated women (aRR, 1.24; 95% confidence interval [CI], 1.19-1.30). Adjusting the retesting window to 21 to 180 days (aRR, 1.24; 95% CI, 1.19-1.30) and 28 to 180 days (aRR, 1.25; 95% CI, 1.19-1.30) did not alter our primary findings.
Conclusions: Persistent/recurrent urogenital CT may be more common among women treated with azithromycin than with doxycycline.
The reason for this difference is uncertain and is an important area of future investigation.
C hlamydia trachomatis (CT) is the most commonly reported infection in the United States, with more than 1 million cases reported among women in 2016. 1 The rate of CT among women has increased by 6.2% since 2013 and was 657.3 cases per 100,000 women in 2016. 1 Persistent or recurrent urogenital CT is common after treatment, with an estimated 20% of women experiencing repeat urogenital CTwithin 12 months after an initial CT diagnosis. 2 If untreated, urogenital CT can lead to pelvic inflammatory disease, ectopic pregnancy, and tubal factor infertility. Repeat CT infections are associated with an increased risk of these reproductive tract sequelae. 3 Recent studies have highlighted the potential importance of rectal CT in women. Rectal CT is common among female sexually transmitted disease (STD) clinic patients-with prevalence estimates ranging from 3% to 57% 4 -and is not necessarily associated with reporting anal intercourse. [5] [6] [7] [8] Autoinfection of CT from the vagina to the rectum 5, 6 or from the rectum to the vagina 9, 10 may occur. The latter has been demonstrated in animal models, 9 and in women, it is likely facilitated by the close proximity of the vagina and anus. If autoinfection does occur, inadequately treated rectal CT could serve as a source of persistent/recurrent urogenital CT in women. Currently, the Centers for Disease Control and Prevention (CDC) recommends azithromycin (1 g orally once) or doxycycline (100 mg orally twice daily for 7 days) for the treatment of CT, 11 based on evidence that the 2 therapies are similarly efficacious in the treatment of urogenital CT. 12 However, azithromycin seems to be substantially less effective than doxycycline in the treatment of rectal CT. 13 Given that 70% to 89% of women with urogenital CT have concurrent rectal CT 5, 6, [14] [15] [16] and that azithromycin may not be as effective as doxycycline for rectal CT, if autoinfection from the rectum to the vagina frequently occurs, one would expect that long-term follow-up studies of women with urogenital CT would demonstrate that azithromycin-treated women have a greater risk of persistent/recurrent urogenital CT than do doxycyclinetreated women. To provide support to this hypothesis, we leveraged Washington State's (WA's) electronic CT surveillance data to conduct a population-based cohort study of all women with urogenital CT during a 24-year period. Our primary goal was to estimate the risk of persistent/recurrent urogenital CT among women treated with azithromycin compared with doxycycline.
MATERIALS AND METHODS

Study Design and Population
We used chlamydia surveillance data to create a populationbased retrospective cohort of all women in WA 14 years or older 
Data Collection and Measures
All data for this study were obtained from WA Department of Health (DOH)'s electronic STD surveillance database (PHIMS-STD), which includes data from laboratories, medical providers (via case report forms), and partner services interviews. Washington State laws require laboratories and medical providers to report all CT cases to local health authorities, who subsequently provide case report and interview data to WA DOH via PHIMS-STD. PHIMS-STD is a person-based system that allows the identification of repeat infections. Users must search for an existing person in PHIMS-STD before entering a new case. Washington State DOH uses Registry Plus LinkPlus software, a probabilistic record linkage program, to identify duplicate patients. The start date for this study reflects the year when surveillance data become available electronically.
Demographic information, date of diagnosis and treatment, treatment provided, anatomic site of infection, pregnancy status, and gonorrhea coinfection were obtained from PHIMS-STD. Case report data recorded in PHIMS-STD also include information on reason for examination, which includes 3 fixed response options: symptoms, routine examination (no symptoms), and exposed to infection. In WA, field services staff routinely contact medical providers if a case report form is not submitted or if treatment information on the case report form is incomplete.
We defined urogenital CT as a positive laboratoryconfirmed chlamydia test result where the case report form indicated the anatomic site of infection as the cervix, urethra, urine, or vagina. Surveillance data do not include information on the method of CT testing (i.e., culture or nucleic acid amplification test [NAAT] ). However, NAAT for chlamydia became widespread in WA in the mid to late 1990s.
Definition of Treatment and Outcome
This analysis only includes women who received azithromycin or doxycycline, per the case report data. We assumed that women who were treated with azithromycin or doxycycline received the regimen consistent with the CDC treatment guidelines 11 ; we excluded women from the analysis if there was evidence that a woman received a dose that was inconsistent with the CDC guidelines (e.g., 2 g azithromycin).
We defined our primary outcome, persistent/recurrent urogenital CT, as the first positive urogenital CT test result in the surveillance data that occurred 14 to 180 days after treatment of the initial infection. Because surveillance data only include information on positive CT test results, women without a repeat positive urogenital CT test result within 14 to 180 days include women who were not retested for CT during that period and women who were retested for CT during that period but retested negative.
Statistical Analysis
We used χ 2 tests to compare characteristics of women who received azithromycin versus doxycycline. For our primary analysis, we used χ 2 tests to compare the proportion of women with persistent/recurrent urogenital CT 14 to 180 days after treatment who were treated with azithromycin versus doxycycline. We used log binomial regression models with robust variances to estimate the unadjusted and adjusted relative risk (aRR) and corresponding 95% confidence intervals (CIs) of persistent/recurrent infection associated with treatment with azithromycin versus doxycycline. We adjusting for the following factors: age (continuous), race/ ethnicity, year of diagnosis (continuous), gonorrhea coinfection, pregnancy status, reason for examination (including a category for missing), and county where the case was reported. We also report the association between each confounder and persistent/ recurrent urogenital CT. Because a repeat positive CT NAAT test result within 21 days of treatment may be a false positive due to the presence of nonviable organisms, 17 in a sensitivity analysis, we repeated these analyses using 2 alternative outcome windows (21-180 and 28-180 days after treatment).
We conducted 3 secondary analyses. First, to more closely align this analysis with previous studies comparing the 2 therapies in the treatment of urogenital CT, 12 we stratified the retesting window (i.e., the number of days from the date of treatment to the date of the repeat positive test result) into 4 categories: 14-30, 30-60, 61-90, and 91-180 days. Second, to reduce the possible effect of antibiotic treatment of gonorrhea coinfection on our results, we excluded women with gonorrhea coinfection from the multivariate model. Third, to examine if reported exposure to CT was similar for women treated with azithromycin or doxycycline during the time between treatment of the initial infection and the repeat positive test result, we compared the distribution of reasons for receiving the repeat CT test among women with a positive repeat CT test result 14 to 180 days after treatment.
All analyses were performed using Stata statistical software, version 13.1 (StataCorp, College Station, TX). Tests were performed at a significance level of 0.05. Study procedures and analyses were approved by the University of Washington Human Subjects Division.
RESULTS
Between January 1, 1992, and December 31, 2015, there were 299,256 CT cases among women 14 years or older in WA, of which 268,595 (89.7%) were urogenital CT cases (representing 201,536 unique women). Of urogenital CT cases, we excluded 22,898 (8.5%) from this analysis because of missing treatment information (n = 14,969), receipt of a treatment other than azithromycin or doxycycline (n = 5,345), receipt of both azithromycin and doxycycline (n = 2,554), or receipt of a nonrecommended regimen for uncomplicated CT (n = 30). Among urogenital cases who received either azithromycin (n = 176,279; 65.6%) or doxycycline (n = 69,422; 25.8%), we further excluded 10,965 (4.6%) cases because of missing treatment date (n = 6764) or a repeat test earlier than 14 days after treatment (n = 4201); these were not proportionately different between women who received azithromycin or doxycycline. The final analytic sample included 168,301 urogenital CT cases treated with azithromycin and 66,432 urogenital CT cases treated with doxycycline.
Three quarters of women with urogenital CT were younger than 25 years; approximately half were white, non-Hispanic; and one third were diagnosed in 2011 through 2015 (Table 1) . Compared with women treated with azithromycin, women treated with doxycycline were more likely to be white, non-Hispanic; to be symptomatic; and to have been diagnosed before 2006.
Of 234,733 women treated with azithromycin or doxycycline, 14,382 (6.1%) had persistent/recurrent urogenital CTwithin 14 to 180 days after treatment, including 11,242 (6.7%) women treated with azithromycin and 3140 (4.7%) treated with doxycycline (P < 0.001; Table 2 ). Of 14,382 women with persistent/ recurrent urogenital CT 14 to 180 days after treatment, approximately 9% (n = 1230) were retested within 30 days of treatment and 72% (n = 10,308) were retested after 60 days. The difference in the percentage of women with persistent/recurrent urogenital CT for azithromycin versus doxycycline ranged from 0.2 percentage points for women retested within 30 days to 0.8 percentage points for women retested 91 to 180 days after treatment ( Among all women with an initial urogenital CT test, those aged 14 to 17 years had the highest risk (9.1%) of persistent/ recurrent urogenital CT, and each 1-year increase in age was associated with a 6% lower risk of persistent/recurrent urogenital CT Table 3 ). Other factors significantly associated with an increased risk of persistent/recurrent urogenital CT were being nonwhite, having concurrent gonorrhea, having a symptomatic infection, and year of diagnosis (Table 3) . Table 4 describes the reason for receiving a repeat CT test, among the 14,382 women with a repeat positive urogenital CT test result 14 to 180 days after treatment. Compared with women treated with azithromycin, women initially treated with doxycycline were more likely to receive a repeat CT test because of symptoms and less likely to receive a repeat CT test as part of a routine examination. However, a similar proportion of women initially treated with azithromycin or doxycycline received a repeat test because they had been exposed to CT (11.1% vs. 10.5%, respectively).
DISCUSSION
In this population-based study of 234,733 women with urogenital CT, we found that 6.1% of women had persistent/recurrent urogenital CT within 6 months of treatment, and this risk was higher for women treated with azithromycin (6.7%) compared with doxycycline (4.7%). The RR of persistent/recurrent urogenital CT was significantly higher for women treated with azithromycin versus doxycycline (RR, 1.41; 95% CI, 1.36-1.47) and remained elevated (aRR, 1.24; 95% CI, 1.19-1.30) after adjustment for several confounding factors. This finding did not appreciably change when we altered the repeat testing window from 14-180 days to 21-180 or 28-180 days. Although there are a number of possible explanations for our findings, we believe that this study lends support to the hypothesis that undiagnosed and inadequately treated rectal CT may be a source of persistent/recurrent urogenital CT in women.
Our findings are in the range of those from several randomized controlled trials (RCTs) comparing azithromycin and doxycycline in the treatment of urogenital CT. In RCTs that included women with follow-up testing within 1 to 6 weeks after treatment, the percentage of individuals with persistent/recurrent urogenital CT ranged from 0.0% to 11.8% for those treated with azithromycin and 0.0% to 12.5% for those treated with doxycycline. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] A metaanalysis of these RCTs found a pooled fixed-effects efficacy difference for women (efficacy for doxycycline minus efficacy for azithromycin) of 0.5 (95% CI, −4.9 to 5.8). 12 However, the most recent RCT on this topic, which used a 28-day follow-up period, found that the absolute risk of treatment failure was 1.9 percentage points higher in women treated with azithromycin compared with doxycycline. 30 Despite the methodologic differences between our study and the RCTs-differences in study design (retrospective cohort vs. RCT), follow-up method (passive versus active), and follow-up time (6 months vs. 1-6 weeks)-we similarly observed a 2.0-percentage-point difference in favor of doxycycline and found that the proportion of women with persistent/recurrent urogenital CT (6.7% for azithromycin and 4.7% for doxycycline) is within the range reported in previous studies.
Although our study does not directly assess whether the rectum is a source of persistent/recurrent urogenital CT among women, these findings add support to the hypothesis that prevalent and inadequately treated rectal CT may lead to subsequent autoinfection from the rectum to the urogenital tract. Because rectal CT screening among women is not routine in WA, we do not have data on how many women in this study had concurrent rectal CT. However, an estimated 70% to 89% of women with urogenital CT have concurrent rectal CT 5, 6, [14] [15] [16] ; thus, a substantial portion of these women may have also had undiagnosed rectal CT. If azithromycintreated women were less likely to clear their rectal infection than doxycycline-treated women 13 and autoinfection from the rectum to the vagina did occur, this may explain the increased risk of persistent/recurrent urogenital CT that we observed. Notably, it is possible that autoinfection from the rectum to the urogenital tract, if it does occur, may take several weeks. Tests-of-cure performed in the first few weeks after therapy may be too early to detect recurrent infection due to autoinoculation. Our study somewhat supports this hypothesis, as the absolute difference in the percentage of women with persistent/recurrent infection (azithromycin minus doxycycline) increased from 0.2 percentage points in the first 30 days after treatment to 1.8 percentage points after 30 days of treatment.
There are also a number of alternative explanations for why women treated with azithromycin had a higher risk of persistent/ recurrent urogenital CT in this study. First, it is possible that women treated with azithromycin were more likely to be reexposed to CT compared with those treated with doxycycline. However, in our study, at least among women who retested CT positive, the proportion for whom reexposure was documented as the reason for the repeat CT test was similar (11%) for women treated with azithromycin or doxycycline. This suggests a nondifferential risk of reexposure by therapy received, although this is only known or suspected reexposure. Second, women who were treated with azithromycin may have been more likely to retest for CT within 6 months of treatment, which may have increased CT case finding in that group. In 2002, CDC modified CT screening guidelines to suggest that clinicians "consider" rescreening patients after treatment, and the 2010 guidelines firmly recommend rescreening. This change in guidelines occurred during a period of increasing azithromycin use in WA; thus, it is possible that azithromycintreated women were more often retested than those treated with doxycycline. Unfortunately, we have no information on the proportion of women who retested within 6 months of treatment or if this proportion differs by therapy received. However, in our multivariate model, we did include year of diagnosis to account for this secular trend. Fourth and similarly, azithromycin use in WA increased concurrently with an increase in the use of NAAT for chlamydia. Thus, the higher risk of persistent/recurrent urogenital CT we observed among azithromycin-treated women may be due to the use of a more sensitive test among the azithromycin-treated cases. Surveillance data do not include information on the type of test (culture vs. NAAT) that was used, but as stated earlier, our multivariate models were adjusted for year of diagnosis, which does address this secular trend. Fifth, there may be factors specific to the therapies-such as peak drug levels of duration above the minimum inhibitory concentration-that influenced the results. Finally, azithromycin may in fact be less effective than doxycycline to treat urogenital CT and may be influenced by other (often unmeasured) factors such as the microbiome. 10 This study has several strengths. This is a population-based study of more than 230,000 women with urogenital CT and efforts by field services staff to document treatment of CT cases resulted in less than 6% of cases with incomplete treatment information. There are also many key limitations. First, these are surveillance data and there was no active follow-up of women in this cohort. Thus, this study likely underestimates the true proportion of women with persistent/recurrent CT. Second, women without a repeat positive test result includes women who retested negative for CTwithin 6 months of treatment and those who did not retest at all. Differential retesting by therapy may have influenced our findings, although the extent of this is unknown. Third, we cannot eliminate the possibility that our findings may be due to confounding. Our multivariate model included several possible confounding factors, but there may be other factors, particularly risk for reexposure, that were unavailable in surveillance data. Fourth, we cannot distinguish between persistent or recurrent infection. It is likely that many of the persistent/recurrent infections we observed were the result of reinfections. This may have influenced our findings if women treated with azithromycin were more likely to be reinfected compared with women treated with doxycycline. Fifth, as described earlier, azithromycin use increased in WA concurrently with an increase in NAAT testing and a change in the rescreening guidelines. We addressed this by including year of initial CT diagnosis in our multivariate model, but this secular trend is still key a confounder. Sixth, although we excluded only 8.5% of CT cases from this analysis because of missing treatment information, one half of those cases occurred before 2000; thus, there was differential exclusion by year. Seventh, data on symptomatic cases are from the "reason for examination" field in the case report form and may not completely capture all true symptomatic cases. Finally, WA surveillance data do not include information on bacterial vaginosis diagnosis or metronidazole use. This may be an important unmeasured confounder in this analysis, because bacterial vaginosis may contribute to CT acquisition. In conclusion, we found that women with urogenital CT treated with azithromycin were more likely to have persistent/ recurrent urogenital CT within 6 months compared with those treated with doxycycline. This finding is consistent with our underlying hypothesis that use of a drug that inadequately treats rectal infections would lead to a higher risk of persistent or recurrent urogenital CT, and supports a growing body of literature suggesting that undiagnosed rectal CT infection may play a role in women's reproductive health. However, the importance of rectal CT as a contributor to persistent/recurrent urogenital CT among women remains uncertain. We still do not know how long rectal CT persists, how often positive NAAT results for rectal specimens represent true infections, and if and how often women autoinoculate infections from the rectum to the urogenital tract. We also do not have definitive data regarding the relative efficacy of doxycycline and azithromycin in the treatment of rectal CT. Answers to these outstanding questions and others may influence CT screening and treatment guidelines for women.
